Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors

Condition:   Hepatocellular Carcinoma Intervention:   Drug: Anlotinib and TQB2450 Sponsors:   Shanghai Zhongshan Hospital;   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials